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Several biomarkers have been explored 4, 5 in diseases treated with rituximab; however, all require validation before they can enter clinical practice; among them, a role for candidate single nucleotide polymorphisms (SNPs) has been proposed. 6 However, no SNP has so far shown a reliable association with response to treatment and no such study has been performed in AAV. We tested a panel of candidate SNPs to investigate their potential association with response to rituximab in 2 large cohorts of patients with AAV.
We included patients with granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) who received rituximab mainly for relapsing or refractory disease. We aimed at identifying associations between the tested SNPs and the rate of rituximab failure at 6 months and time to rituximab failure (relapse). For further details, see the Methods section in this article's Online Repository at www.jacionline.org.
We enrolled 213 patients in the primary and 109 in the replication cohort (see Table E1 in this article's Online Repository at www.jacionline.org). Across the primary cohort, a mean of 0.88 6 0.19 SNPs per sample could not be called and no SNP had a P value of less than .05 for departure from HardyWeinberg Equilibrium (HWE) (see Table E2 in this article's Online Repository at www.jacionline.org).
In the primary cohort, the TNFSF13B SNP rs3759467 was associated with time to rituximab failure (P 5 2.86 3 10 204 , Pcorr 5 .01) (Fig 1, A; see Table E3 in this article's Online Repository at www.jacionline.org). We genotyped this SNP in the replication cohort (test for deviation from HWE P 5 .7627; rate of missing calls, 3%) where the association with time to rituximab failure was confirmed (P 5 .002) (Fig 1, B) .
Because the results suggested a recessive effect for the SNP rs3759467, we used recessive models for the analysis in the replication cohort and reanalysis of the primary cohort. Metaanalyses of the 2 cohorts confirmed an association between the TNFSF13B SNP rs3759467 and the 2 end points (P 5 .0065 and 8.5 3 10 206 , respectively) ( Table I) . We then compared the main clinical characteristics of the carriers of the CC genotype with the carriers of the TC and TT genotypes (see Table E4 in this article's Online Repository at www.jacionline.org) and found a higher rate of detectable peripheral B cells 6 months after rituximab in carriers of the CC genotype (50% vs 14%; P 5 .0146) as well as a smaller reduction in IgM levels (1.5 [1.4-10.92 ] and 1 [1-1.33 ]; P 5 .01539).
The haplotype analyses of the 59 regulatory region of the TNFSF13B gene based on the genotyped SNPs confirmed an association of the risk of rituximab failure at 6 months for the haplotype including the risk allele of the SNP rs3759467 (see Table E5 in this article's Online Repository at www.jacionline. org).
In view of the small number of MPO-ANCA-positive patients and the fact that all the minor homozygous carriers for the rs3759467 SNP were PR3-ANCA positive, we reanalyzed the primary cohort according to ANCA specificity (see Table E6 in this article's Online Repository at www.jacionline.org); the association with the B-cell activating factor (BAFF) SNP rs3759467 was limited to the PR3-ANCA subgroup (see Tables E6 and E7 in this article's Online Repository at www.jacionline.org).
In the MPO-ANCA subgroup, a different association emerged in the primary cohort with the SNP rs6822844 in the IL2-IL21 area (rituximab failure risk at 6 months and time to rituximab failure, P 5 4.2 3 10 204 -Pcorr 5 .03 and P 5 1.9 3 10 204 -Pcorr 5 .0068, respectively) (Table E6 ). However, this was not replicated (rituximab failure risk at 6 months and time to rituximab failure, P 5 .153 and .172, respectively) in the context of a small sample size (19 patients), although there was a trend to an increased risk of treatment failure at 6 months for the carriers of the T allele (see Table E8 in this article's Online Repository at www.jacionline.org).
We have identified an SNP (rs3759467) in the 59 regulatory region of the gene TNFSF13B (BAFF) able to predict response to rituximab in 2 cohorts of patients with AAV. Interestingly, the carriers of the unfavorable genotype showed in addition to a poor response to rituximab, a higher proportion of detectable B cells 6 months after infusion and a smaller reduction in IgM levels.
A BAFF level increase after rituximab treatment has been described and a central role for this cytokine in AAV pathogenesis has also been proposed. 7 The 59 regulatory region of the BAFF gene includes several SNPs that may have a modulatory effect; the -TTTT-haplotype of this region has been associated with BAFF levels 8 and response to rituximab in rheumatoid arthritis.
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In our study, a trend toward better response in carriers of this haplotype was also observed. The role of the SNP rs3759467 will need to be clarified; this is part of a TAAT-binding site; the lack of a heterozygous effect may suggest that the losing of both sites is required to obtain the phenotype causing poor response. It seems likely that this SNP modulates B-cell survival and/or activity; this might be a consequence of higher baseline BAFF levels or greater BAFF increases after a B-cell-depleting event.
Interestingly, our findings were restricted to the subgroup of patients with positive PR3-ANCA probably due to power limitations in the MPO-ANCA subgroup where the reanalyses identified a different association in the IL2-IL21 area, as already described in systemic lupus erythematosus. Our study has limitations: a sample size relatively small for a genetic study and the retrospective nature of data collection may be weaknesses; however, at the time of this writing, it would not have been possible to enroll a comparable prospective cohort. We also have to acknowledge the closeness of the P value for the departure from HWE for the SNP rs3759467 in the primary cohort; however, the replication of the data in the context of a P value for the departure from HWE far from significance (P 5 .7627) is reassuring on the reliability of the overall finding. In conclusion, we have identified a TNFSF13B (BAFF) SNP (rs3759467) associated with response to rituximab in 2 independent cohorts of patients with AAV. This SNP may be useful in identifying patients likely to respond poorly to rituximab and for whom alternative treatments should be considered. Further studies are required to confirm this finding and to clarify its mechanism of action. 
End points
The end points of the study were to identify associations between the tested SNPs and the rate of rituximab failure at 6 months and time to rituximab failure (relapse) within 12 months of the first rituximab administration. We defined rituximab failure as active vasculitis requiring escalation of immunosuppressive treatment. SNPs showing an association with at least 1 of the 2 end points in the primary cohort were analyzed in the replication cohort for confirmation and then meta-analyses of the results were performed. Subgroup analyses were performed after merging the 2 cohorts.
Genotyping
Eighteen candidate SNPs were chosen according to a biological rationale or previous reports (Table E2) .
E3-E8 DNA was extracted from peripheral blood using the Qiagen DNA extraction kit; genotyping was performed using TaqMan and Sequenom platforms with the exception of the FCGR2B SNP rs1050501, which was genotyped via a ''modified'' TaqMan approach as previously described.
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Statistics
Statistical analysis was performed using the software R (http://www.rproject.org) and the packages coin, E10 survival, E11 SNPassoc, E12 and hapassoc. E13 For exploratory purposes, the primary cohort has been analyzed using the Cochrane-Armitage test with log-additive model. As a result of the exploratory analysis (recessive mechanism for the SNP rs3759467), the replication cohort has been analyzed immediately using a recessive model of the same test. We have then reanalyzed the primary cohort with the same model and a meta-analysis has been performed.
The time to rituximab failure has been assessed by Kaplan-Meier survival analysis and a log-rank test has been used to compare populations. Coxproportional hazards regression model has been used for reanalyses of the time to rituximab failure in the primary and replication cohort using a recessive model and the results have been used for meta-analyses for this end point.
Delta of reduction of IgG and IgM levels has been assessed as the ratio between the baseline value and the value at the time point of interest.
Results are expressed as value and percentage for categorical variables and median and interquartile range or mean and SEM for continuous variables when appropriate.
In view of the observation of an association in the 59 regulatory region of the gene TNFSF13B, we decided to study the haplotypes of this region because 4 of the SNPs included in the study were in strong linkage disequilibrium and organized in well-renowned haplotype blocks. We used the R package hapassoc E13 for the identification of the haplotypes and the Cochrane-Armitage test to explore association between haplotypes and the risk of treatment failure 6 months after treatment with rituximab.
Meta-analyses were performed via a fixed-effects weighted method using the Linux version of the software metal (http://csg.sph.umich.edu/abecasis/Metal/ download/). Bonferroni corrections for multiple testing were performed, with corrected P (Pcorr) values of less than .05 considered significant.
LETTER TO THE EDITOR 3.e2 Results are expressed as n/N (%) or median (IQR) when appropriate. ENT, Ear, nose and throat; IV, intravenous; MMF, mycophenolate mofetil. *Other. Includes first presentation of disease, contraindication to standard treatment, grumbling disease, patients unable to taper the prednisolone dose, need for steroid-free regimen. tOther. Includes 500 mg 2 weeks apart (2 cases), administration of a single dose of 1 g of rituximab (1 case), administration of 3 doses of rituximab at the dose of 375 mg/m 2 . tExcluding oral steroids, but including oral immunosuppressive agents continued for at least 3 months after the administration of the first rituximab dose. The test for deviation from HWE has been calculated using the R package SNPasso, E12 and threshold for significance has been established to P < .05. MAF, Minor allele frequency.
LETTER TO THE EDITOR 3.e4 Results are expressed as n/N (%) or median (IQR) when appropriate. B-cell return has been defined as B-cell count > _ 0.01 3 10 9 /L. *Active flare defined as rituximab given either for relapsing or for refractory disease. tStatistically significant. tDelta has been calculated as the ratio between the value at the time of rituximab administration and the value at the time point of interest. Associations have been tested using the Mann-Whitney rank sum test. Rituximab failure rates at 6 mo were compared using a Cochrane-Armitage test with log-additive model and time to rituximab failure using log-rank test. *Statistically significant. Rituximab failure risk at 6 months has been explored using a recessive model of the Cochrane-Armitage test. Time to rituximab failure has been explored using a recessive model of Cox-proportion hazards regression model. 
